Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Infect Dis ; 124 Suppl 1: S56-S62, 2022 Nov.
Article in English | MEDLINE | ID: mdl-35231610

ABSTRACT

BACKGROUND: Tuberculosis (TB) prevalence is high among socially marginalized citizens in Denmark, and management of latent TB infection (LTBI) may be part of preventing new cases. Patients with LTBI are offered either preventive treatment (TPT) or follow-up chest x-rays, but knowledge about the long-term outcome in terms of active TB is sparse. METHODS: We performed a retrospective cohort study investigating the long-term outcomes for socially marginalized citizens who were diagnosed with LTBI or who had a positive interferon-gamma release assay (IGRA) but were lost to follow-up. Information on TB examinations, diagnostics, and treatment along with data on death were gathered from medical records from the date of positive IGRA to February 1, 2021. RESULTS: We identified 119 patients with LTBI, 18 of which (15.1%) were diagnosed with TB during the follow-up period (mean, 4.5 years). TPT was completed by 36.1% and the TB incidence rate ratio of those completing TPT to those who did not was 0.78 (confidence interval, 0.25-2.17; P =.6). Of the patients with TB, 16 of 18 achieved treatment success. CONCLUSION: High rates of TB development are found among socially marginalized citizens with LTBI. Overall incidence of TB was not significantly reduced by administration of TPT, although TB did not develop in the first 2 years following TPT.


Subject(s)
Latent Tuberculosis , Tuberculosis , Humans , Latent Tuberculosis/diagnosis , Latent Tuberculosis/drug therapy , Latent Tuberculosis/epidemiology , Tuberculin Test , Incidence , Cohort Studies , Retrospective Studies , Interferon-gamma Release Tests , Tuberculosis/diagnosis , Tuberculosis/drug therapy , Tuberculosis/epidemiology
2.
Front Immunol ; 11: 1112, 2020.
Article in English | MEDLINE | ID: mdl-32595636

ABSTRACT

Toll-like receptors (TLRs) are a family of pattern recognition receptors and part of the first line of defense against invading microbes. In humans, we know of 10 different TLRs, which are expressed to varying degrees in immune cell subsets. Engaging TLRs through their specific ligands leads to activation of the innate immune system and secondarily priming of the adaptive immune system. Because of these unique properties, TLR agonists have been investigated as immunotherapy in cancer treatment for many years, but in recent years there has also been growing interest in the use of TLR agonists in the context of human immunodeficiency virus type 1 (HIV-1) cure research. The primary obstacle to curing HIV-1 is the presence of a latent viral reservoir in transcriptionally silent immune cells. Due to the very limited transcription of the integrated HIV-1 proviruses, latently infected cells cannot be targeted and cleared by immune effector mechanisms. TLR agonists are very interesting in this context because of their potential dual effects as latency reverting agents (LRAs) and immune modulatory compounds. Here, we review preclinical and clinical data on the impact of TLR stimulation on HIV-1 latency as well as antiviral and HIV-1-specific immunity. We also focus on the promising role of TLR agonists in combination strategies in HIV-1 cure research. Different combinations of TLR agonists and broadly neutralizing antibodies or TLRs agonists as adjuvants in HIV-1 vaccines have shown very encouraging results in non-human primate experiments and these concepts are now moving into clinical testing.


Subject(s)
HIV Infections/immunology , HIV Infections/therapy , HIV-1 , Immunotherapy/methods , Toll-Like Receptors/agonists , AIDS Vaccines/administration & dosage , Adjuvants, Immunologic/administration & dosage , Animals , Anti-HIV Agents/pharmacology , Broadly Neutralizing Antibodies/administration & dosage , Clinical Trials as Topic , HIV Antibodies/administration & dosage , HIV-1/drug effects , HIV-1/immunology , HIV-1/physiology , Humans , Immune Checkpoint Inhibitors/administration & dosage , Immunologic Factors/pharmacology , In Vitro Techniques , Models, Immunological , Primates , Pteridines/pharmacology , Toll-Like Receptor 3/agonists , Toll-Like Receptor 7/agonists , Toll-Like Receptor 9/agonists , Virus Latency/drug effects , Virus Latency/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...